Drugs & Aging

, Volume 29, Issue 3, pp 243–248

Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

  • Lesley J. Scott
  • Lily P. H. Yang
  • Katherine A. Lyseng-Williamson
Adis Drug Clinical Q&A

DOI: 10.2165/11209160-000000000-00000

Cite this article as:
Scott, L.J., Yang, L.P.H. & Lyseng-Williamson, K.A. Drugs Aging (2012) 29: 243. doi:10.2165/11209160-000000000-00000

Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Lily P. H. Yang
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand